المؤلفون: Yi Yang, Bo Chen, Chongming Zheng, Hao Zeng, Junxi Zhou, Yaqing Chen, Qing Su, Jingxian Wang, Juejin Wang, Yurong Wang, Hongli Wang, Ruxue Jin, Zhiyuan Bo, Gang Chen, Yi Wang

المصدر: Cell & Bioscience, Vol 14, Iss 1, Pp 1-15 (2024)

مصطلحات موضوعية: Glucose-lowering drug target, Gastrointestinal cancer risk, Causality, Mendelian randomization, Biotechnology, TP248.13-248.65, Biology (General), QH301-705.5, Biochemistry, QD415-436

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-3701Test

الوصول الحر: https://doaj.org/article/56fddb8011ae426aa04bee4c06fbc237Test

المؤلفون: Bongaerts, Brenda, Kuss, Oliver, Bonnet, Fabrice, Chen, Hungta, Cooper, Andrew, Fenici, Peter, Gomes, Marilia B., Hammar, Niklas, Ji, Linong, Khunti, Kamlesh, Medina, Jesús, Nicolucci, Antonio, Shestakova, Marina V, Watada, Hirotaka, Rathmann, Wolfgang

المساهمون: Heinrich Heine Universität Düsseldorf = Heinrich Heine University Düsseldorf, Université de Rennes (UR), AstraZeneca Cambridge, UK, Università cattolica del Sacro Cuore Milano (Unicatt), Universidade do Estado do Rio de Janeiro Brasil = Rio de Janeiro State University Brazil = Université d'État de Rio de Janeiro Brésil (UERJ), AstraZeneca, People's Hospital of Peking University (PKUPH), University of Leicester, Juntendo University Hospital Tokyo, Saint Luke's Mid America Heart Institute, Kansas City, MO, USAOpen Access funding enabled and organized by Projekt DEAL.

المصدر: ISSN: 1462-8902.

مصطلحات موضوعية: glucose-lowering drug, glycaemic control, observational study, type 2 diabetes, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36906837; hal-04090018; https://hal.science/hal-04090018Test; PUBMED: 36906837

الإتاحة: https://doi.org/10.1111/dom.15050Test
https://hal.science/hal-04090018Test

المصدر: The PRACTICAL Consortium 2023 , ' Genetically proxied glucose-lowering drug target perturbation and risk of cancer : a Mendelian randomisation analysis ' , Diabetologia , vol. 66 , no. 8 , pp. 1481-1500 . https://doi.org/10.1007/s00125-023-05925-4Test

مصطلحات موضوعية: ABCC8, Breast cancer, Colorectal cancer, GLP1R, Glucose-lowering drug targets, Mendelian randomisation, PPARG, Prostate cancer, Genome-Wide Association Study, Humans, Risk Factors, Colorectal Neoplasms/genetics, Male, Glucose, Polymorphism, Single Nucleotide/genetics, Diabetes Mellitus, Type 2/drug therapy, Prostatic Neoplasms/complications, Mendelian Randomization Analysis, Breast Neoplasms/genetics, PPAR gamma/genetics

العلاقة: https://pure.au.dk/portal/en/publications/ccc37670-0dee-479b-bd77-1f542cb4bd93Test

الإتاحة: https://doi.org/10.1007/s00125-023-05925-4Test
https://pure.au.dk/portal/en/publications/ccc37670-0dee-479b-bd77-1f542cb4bd93Test
http://www.scopus.com/inward/record.url?scp=85164210817&partnerID=8YFLogxKTest

المؤلفون: Brenda Bongaerts, Oliver Kuss, Fabrice Bonnet, Hungta Chen, Andrew Cooper, Peter Fenici, Marilia B Gomes, Niklas Hammar, Linong Ji, Kamlesh Khunti, Jesus Medina, Antonio Nicolucci, Marina V Shestakova, Hirotaka Watada, Wolfgang Rathmann

مصطلحات موضوعية: Uncategorized, glucose-lowering drug, glycaemic control, observational study, type 2 diabetes

العلاقة: 2381/22787384.v1; https://figshare.com/articles/journal_contribution/HbA_sub_1c_sub_trajectories_over_3_years_in_people_with_type_2_diabetes_starting_second-line_glucose-lowering_therapy_The_prospective_global_DISCOVER_study_/22787384Test

الإتاحة: https://figshare.com/articles/journal_contribution/HbA_sub_1c_sub_trajectories_over_3_years_in_people_with_type_2_diabetes_starting_second-line_glucose-lowering_therapy_The_prospective_global_DISCOVER_study_/22787384Test

المؤلفون: T. B. Morgunova, I. V. Glinkina, E. D. Pesheva, A. A. Zorina, V. V. Fadeev, Т. Б. Моргунова, И. В. Глинкина, Е. Д. Пешева, А. А. Зорина, В. В. Фадеев

المصدر: Meditsinskiy sovet = Medical Council; № 13 (2023); 122-129 ; Медицинский Совет; № 13 (2023); 122-129 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: терапевтическое применение, glucose lowering drug, metformin, glycemic control, therapeutic use, сахароснижающий препарат, метформин, гликемический контроль

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7720/6855Test; Дедов И.И., Шестакова М.В., Майоров А.Ю. (ред.). Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 11-й выпуск. М.; 2023. 234 с. Режим доступа: https://webmed.irkutsk.ru/doc/pdf/algosd.pdfTest.; Montvida O., Shaw J., Atherton J.J., Stringer F., Paul S.K. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes. Diabetes Care. 2018;41(1):69–78. https://doi.org/10.2337/dc17-1414Test.; Maruthur N.M., Tseng E., Hutfless S., Wilson L.M., Suarez-Cuervo C., Berger Z. et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med. 2016;164(11):740–751. https://doi.org/10.7326/M15-2650Test.; Fang M., Wang D., Coresh J., Selvin E. Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018. N Engl J Med. 2021;384(23):2219–2228. https://doi.org/10.1056/NEJMsa2032271Test.; Hadden D.R. Goat’s rue – French lilac – Italian fitch – Spanish sainfoin: gallega officinalis and metformin: the Edinburgh connection. J R Coll Physicians Edinb. 2005;35(3):258–260. Available at: https://pubmed.ncbi.nlm.nih.gov/16402501Test.; Keeler R.F., Baker D.C., Evans J.O. Individual animal susceptibility and its relationship to induced adaptation or tolerance in sheep to Galega officinalis L. Vet Hum Toxicol. 1988;30(5):420–423. Available at: https://pubmed.ncbi.nlm.nih.gov/3188360Test.; Bailey C.J., Day C. Traditional plant medicines as treatments for diabetes. Diabetes Care. 1989;12(8):553–564. https://doi.org/10.2337/diacare.12.8.553Test.; Mckendry J.B., Kuwayti K., Rado P.P. Clinical experience with DBI (phenformin) in the management of diabetes. Can Med Assoc J. 1959;80(10):773–778. Available at: https://pubmed.ncbi.nlm.nih.gov/13652024Test.; Bailey C.J. Metformin: historical overview. Diabetologia. 2017;60(9):1566–1576. https://doi.org/10.1007/s00125-017-4318-zTest.; IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med. 2006;23(6):579–593. https://doi.org/10.1111/j.1464-5491.2006.01918.xTest.; Смирнова О.М. Место метформина в современном лечении и профилактике сахарного диабета 2 типа. Сахарный диабет. 2010;13(3):83–90. https://doi.org/10.14341/2072-0351-5494Test.; American Diabetes Association. Standards of Medical Care in Diabetes – 2021. Diabetes Care. 2021;44(Suppl. 1):111–124. https://doi.org/10.2337/dc21-S009Test.; Garber A.J., Handelsman Y., Grunberger G., Einhorn D., Abrahamson M.J., Barzilay J.I. et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm – 2020. Endocr Pract. 2020;26(1):107–139. https://doi.org/10.4158/CS-2019-0472Test.; Cosentino F., Grant P.J., Aboyans V., Bailey C.J., Ceriello A., Delgado V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. https://doi.org/10.1093/eurheartj/ehz486Test.; Blonde L., Umpierrez G.E., Reddy S.S., McGill J.B., Berga S.L., Bush M. et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan – 2022 Update. Endocr Pract. 2022;28(10):923–1049. https://doi.org/10.1016/j.eprac.2022.08.002Test.; Sanchez-Rangel E., Inzucchi S.E. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60(9):1586–1593. https://doi.org/10.1007/s00125-017-4336-xTest.; Hostalek U., Gwilt M., Hildemann S. Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention. Drugs. 2015;75(10):1071–1094. https://doi.org/10.1007/s40265-015-0416-8Test.; Matthews D.R., Paldánius P.M., Proot P., Chiang Y., Stumvoll M., Del Prato S.; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519–1529. https://doi.org/10.1016/S0140-6736Test(19)32131-2.; Sivitz W.I., Phillips L.S., Wexler D.J., Fortmann S.P., Camp A.W., Tiktin M. et al. Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. Diabetes Care. 2020;43(5):940–947. https://doi.org/10.2337/dc19-1769Test.; Garber A.J., Duncan T.G., Goodman A.M., Mills D.J., Rohlf J.L. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103(6):491–497. https://doi.org/10.1016/s0002-9343Test(97)00254-4.; Mahabaleshwarkar R., DeSantis A. Metformin dosage patterns in type 2 diabetes patients in a real-world setting in the United States. Diabetes Res Clin Pract. 2021;172:108531. https://doi.org/10.1016/j.diabres.2020.108531Test.; Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104–112. https://doi.org/10.14341/DM2004116-17Test.; Ali M.K., Bullard K.M., Saydah S., Imperatore G., Gregg E.W. Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988–2014. Lancet Diabetes Endocrinol. 2018;6(5):392–403. https://doi.org/10.1016/S2213-8587Test(18)30027-5.; Vistisen D., Witte D.R., Brunner E.J., Kivimäki M., Tabák A., Jørgensen M.E., Færch K. Risk of Cardiovascular Disease and Death in Individuals With Prediabetes Defined by Different Criteria: The Whitehall II Study. Diabetes Care. 2018;41(4):899–906. https://doi.org/10.2337/dc17-2530Test.; Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012;35(4):731–737. https://doi.org/10.2337/dc11-1299Test.; Diabetes Prevention Program Research Group. Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care. 2019;42(4):601–608. https://doi.org/10.2337/dc18-1970Test.; Walker E.A., Gonzalez J.S., Tripputi M.T., Dagogo-Jack S., Matulik M.J., Montez M.G. et al. Group. Long-term metformin adherence in the Diabetes Prevention Program Outcomes Study. BMJ Open Diabetes Res Care. 2020;8(1):e001537. https://doi.org/10.1136/bmjdrc-2020-001537Test.; Hughes A., Khan T., Kirley K., Moin T., Mainous A., Sachdev N. et al. Metformin Prescription Rates for Patients with Prediabetes. J Am Board Fam Med. 2022;35(4):821–826. https://doi.org/10.3122/jabfm.2022.04.210485Test.; McCreight L.J., Bailey C.J., Pearson E.R. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426–435. https://doi.org/10.1007/s00125015-3844-9Test.; Bonnet F., Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab. 2017;19(4):473–481. https://doi.org/10.1111/dom.12854Test.; Wee A.K.H., Sultana R. Determinants of vitamin B12 deficiency in patients with type-2 diabetes mellitus – A primary-care retrospective cohort study. BMC Prim Care. 2023;24(1):102. https://doi.org/10.1186/s12875-023-02057-xTest.; Rathis T.S., Ranganathan R.S., Solai Raja M., Srivastav P.S.S. Prevalence of Vitamin B12 Deficiency in Type 2 Diabetes Mellitus Patients on Metformin Therapy. Cureus. 2023;15(4):e37466. https://doi.org/10.7759/cureus.37466Test.; Kim J., Ahn C.W., Fang S., Lee H.S., Park J.S. Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes. Medicine (Baltimore). 2019;98(46):e17918. https://doi.org/10.1097/MD.0000000000017918Test.; Aroda V.R., Edelstein S.L., Goldberg R.B., Knowler W.C., Marcovina S.M., Orchard T.J. et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754–1761. https://doi.org/10.1210/jc.2015-3754Test.; Liu L., Simon B., Shi J., Mallhi A.K., Eisen H.J. Impact of diabetes mellitus on risk of cardiovascular disease and all-cause mortality: Evidence on health outcomes and antidiabetic treatment in United States adults. World J Diabetes. 2016;7(18):449–461. https://doi.org/10.4239/wjd.v7.i18.449Test.; Khunti K., Millar-Jones D. Clinical inertia to insulin initiation and intensification in the UK: A focused literature review. Prim Care Diabetes. 2017;11(1):3–12. https://doi.org/10.1016/j.pcd.2016.09.003Test.; Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854865. Available at: https://pubmed.ncbi.nlm.nih.gov/9742977Test.; Hong J., Zhang Y., Lai S., Lv A., Su Q., Dong Y. et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36(5):1304–1311. https://doi.org/10.2337/dc12-0719Test.; Selvin E., Bolen S., Yeh H.C., Wiley C., Wilson L.M., Marinopoulos S.S. et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008;168(19):2070–2080. https://doi.org/10.1001/archinte.168.19.2070Test.; Han Y., Xie H., Liu Y., Gao P., Yang X., Shen Z. Effect of metformin on allcause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 2019;18(1):96. https://doi.org/10.1186/s12933-019-0900-7Test.; Kim Y., Kim H.S., Lee J.W., Kim Y.S., You H.S., Bae Y.J. et al. Metformin use in el der ly population with diabetes reduced the risk of dementia in a dose-dependent manner, based on the Korean NHIS-HEALS cohort. Diabetes Res Clin Pract. 2020;170:108496. https://doi.org/10.1016/j.diabres.2020.108496Test.; Zhang Q.Q., Li W.S., Liu Z., Zhang H.L., Ba Y.G., Zhang R.X. Metformin therapy and cognitive dysfunction in patients with type 2 diabetes: A meta-analysis and systematic review. Medicine (Baltimore). 2020;99(10):e19378. https://doi.org/10.1097/MD.0000000000019378Test.; https://www.med-sovet.pro/jour/article/view/7720Test

الإتاحة: https://doi.org/10.21518/ms2023-211Test
https://doi.org/10.2337/dc17-1414Test
https://doi.org/10.7326/M15-2650Test
https://doi.org/10.1056/NEJMsa2032271Test
https://doi.org/10.2337/diacare.12.8.553Test
https://doi.org/10.1007/s00125-017-4318-zTest
https://doi.org/10.1111/j.1464-5491.2006.01918.xTest
https://doi.org/10.14341/2072-0351-5494Test
https://doi.org/10.2337/dc21-S009Test
https://doi.org/10.4158/CS-2019-0472Test

المؤلفون: Falkentoft, Alexander C., Gerds, Thomas Alexander, Zareini, Bochra, Knop, Filip K., Køber, Lars, Torp-Pedersen, Christian, Schou, Morten, Bruun, Niels E., Ruwald, Anne Christine

المصدر: Falkentoft , A C , Gerds , T A , Zareini , B , Knop , F K , Køber , L , Torp-Pedersen , C , Schou , M , Bruun , N E & Ruwald , A C 2023 , ' Risk of first-time major cardiovascular event among individuals with newly diagnosed type 2 diabetes : data from Danish registers ' , Diabetologia , vol. 66 , pp. 2017–2029 . https://doi.org/10.1007/s00125-023-05977-6Test

مصطلحات موضوعية: Cardiovascular disease, Glucose-lowering drug, Glycaemic control, Remission of type 2 diabetes, Renin–angiotensin system inhibitor, Statin, Type 2 diabetes

وصف الملف: application/pdf

الإتاحة: https://doi.org/10.1007/s00125-023-05977-6Test
https://curis.ku.dk/portal/da/publications/risk-of-firsttime-major-cardiovascular-event-among-individuals-with-newly-diagnosed-type-2-diabetesTest(8900e8c7-3c5f-4b8b-8d99-e14fc4436953).html
https://curis.ku.dk/ws/files/368619541/s00125_023_05977_6.pdfTest

المؤلفون: Aimin Yang, Hongjiang Wu, Eric S.H. Lau, Xinge Zhang, Mai Shi, Baoqi Fan, Ronald C.W. Ma, Alice P.S. Kong, Andrea O.Y. Luk, Juliana C.N. Chan, Elaine Chow

المصدر: The Lancet Regional Health. Western Pacific, Vol 26, Iss , Pp 100509- (2022)

مصطلحات موضوعية: Glucose lowering drug, Diabetes, Glycemic control, Hypoglycemia, Trends, Diabetes care, Public aspects of medicine, RA1-1270

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2666606522001249Test; https://doaj.org/toc/2666-6065Test

الوصول الحر: https://doaj.org/article/3cbc312b252e40bfa629b92f247146fbTest

المؤلفون: Marília B. Gomes, Fengming Tang, Hungta Chen, Javier Cid-Ruzafa, Peter Fenici, Kamlesh Khunti, Wolfgang Rathmann, Marina V. Shestakova, Filip Surmont, Hirotaka Watada, Jesús Medina, Iichiro Shimomura, Gabriela Luporini Saraiva, Andrew Cooper, Antonio Nicolucci

المصدر: Frontiers in Endocrinology, Vol 13 (2022)

مصطلحات موضوعية: type 2 diabetes, observational study, socioeconomic factors, glycemic control, glucose-lowering drug, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fendo.2022.831676/fullTest; https://doaj.org/toc/1664-2392Test

الوصول الحر: https://doaj.org/article/6c2277abaa80486181f4c6426ca2717cTest

المؤلفون: Marfella R., Prattichizzo F., Sardu C., Rambaldi P. F., Fumagalli C., Marfella L. V., La Grotta R., Frige C., Pellegrini V., D'Andrea D., Cesaro A., Calabro P., Pizzi C., Antonicelli R., Ceriello A., Mauro C., Paolisso G.

المساهمون: Marfella, R., Prattichizzo, F., Sardu, C., Rambaldi, P. F., Fumagalli, C., Marfella, L. V., La Grotta, R., Frige, C., Pellegrini, V., D'Andrea, D., Cesaro, A., Calabro, P., Pizzi, C., Antonicelli, R., Ceriello, A., Mauro, C., Paolisso, G.

مصطلحات موضوعية: Combination therapie, Diabetes algorithm, GLP-1 receptor agonist, Glucose-lowering drug, Heart failure, MACE, Myocardial infarction, SGLT-2 inhibitors

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38184582; info:eu-repo/semantics/altIdentifier/wos/WOS:001137229100003; volume:23; issue:1; firstpage:10; journal:CARDIOVASCULAR DIABETOLOGY; https://hdl.handle.net/11591/517308Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85181474086

الإتاحة: https://doi.org/10.1186/s12933-023-02118-6Test
https://hdl.handle.net/11591/517308Test

المؤلفون: Luis M. Pérez-Belmonte, José David Torres-Peña, María D. López-Carmona, M. Mar. Ayala-Gutiérrez, Francisco Fuentes-Jiménez, Lucía Jorge Huerta, Jaime Alonso Muñoz, Manuel Rubio-Rivas, Manel Madrazo, Marcos Guzmán Garcia, Beatriz Vicente Montes, Joaquim Fernández Sola, Javier Ena, Ruth Gonzalez Ferrer, Carmen Mella Pérez, Carlos Jorge Ripper, Jose Javier Napal Lecumberri, Iris El Attar Acedo, Susana Plaza Canteli, Sara Fuente Cosío, Francisco Amorós Martínez, Begoña Cortés Rodríguez, Pablo Pérez-Martínez, José Manuel Ramos-Rincón, Ricardo Gómez-Huelgas, for the SEMI-COVID-19 Network

المصدر: BMC Medicine, Vol 18, Iss 1, Pp 1-10 (2020)

مصطلحات موضوعية: Type 2 diabetes mellitus, Glucose-lowering drug, Coronavirus disease 2019, Medicine

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s12916-020-01832-2Test; https://doaj.org/toc/1741-7015Test

الوصول الحر: https://doaj.org/article/075d60a7a4074e35b070c9194fc6a79aTest